Skip to main content
Home

Main navigation

  • Company
    • Company profile
    • Leadership team
    • Scientific Advisory Board
    • Board of Directors
  • R&D Programs
    • Pipeline overview
    • DIACC3010
    • DIACC2010/DIACC2020
  • Partnering
  • Media
    • Media hub
    • All press releases
    • All events
    • Media center
  • Careers
  • Contact
  • Search
Diaccurate key achievements

Diaccurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck KGaA

SpaceAdventure

Exploring the new frontiers of oncology

Team Diaccurate

Very serious about incurable diseases

Pipeline

Breaking the impasse with novel therapeutic approaches

Latest news

Diaccurate receives support from Bpifrance to conduct its DIACC2020 Program on the development of new payloads for antibody-drug conjugates (ADCs)

January 5, 2023

Diaccurate welcomes to its Board of Directors Prof. Karine Lacombe, internationally renowned infectious disease specialist and Dr. Catherine George, expert in early drug development

June 24, 2022

Diaccurate appoints Laurence Riot Lamotte as Chief Financial Officer

February 8, 2022
See all press releases

Upcoming events

JP Morgan Healthcare Conference - Biotech Showcase | San Francisco

January 9, 2023 - January 11, 2023

BIO Europe Spring | Basel, Switzerland

March 20, 2023 - March 22, 2023
See all upcoming events

Location

Headquarters: 104 Bd de Sébastopol, 75003 Paris

Lab: 60 avenue André Roussin, 13016 Marseille

  33 (0)1 78 96 41 70

Stay in touch

Subscribe to our newsletter

Contact us

Follow us

   

Footer

  • Legal info
  • Privacy notice
  • Cookies notice